← back to search

Ruth E. Langley

MRC Clinical Trials Unit at UCL · GB
Area of research
Pulmonary and Respiratory Medicine · Surgery
Research interest
Research interests include Gastric Cancer Management and Outcomes, Esophageal Cancer Research and Treatment, Prostate Cancer Treatment and Research, and Inflammatory mediators and NSAID effects.
h-index
42
citations
16,175
works
193
NIH funding
primary concept
Medicine
email

Recent publications

Getting our ducks in a row: The need for data utility comparisons of healthcare systems data for clinical trials
Contemporary Clinical Trials 2024cited by 11position: middledoi
Preoperative Chemoradiotherapy vs Chemotherapy for Adenocarcinoma of the Esophagogastric Junction
JAMA Network Open 2024cited by 10position: middledoi
ARCHERY: a prospective observational study of artificial intelligence-based radiotherapy treatment planning for cervical, head and neck and prostate cancer – study protocol
BMJ Open 2023cited by 15position: lastdoi
Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5‐year follow‐up results from the STAMPEDE randomised trial (NCT00268476)
International Journal of Cancer 2022cited by 74position: middledoi
Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled Trial
JNCI Cancer Spectrum 2022cited by 25position: middledoi
Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials units
Trials 2022cited by 23position: middledoi
Author response to: Increasing frequency of gene copy number aberrations is associated with immunosuppression and predicts poor prognosis in gastric adenocarcinoma
British journal of surgery 2022cited by 0position: middledoi
Development and validation of deep learning classifiers to detect Epstein-Barr virus and microsatellite instability status in gastric cancer: a retrospective multicentre cohort study
The Lancet Digital Health 2021cited by 120position: middledoi
Accessing routinely collected health data to improve clinical trials: recent experience of access
Trials 2021cited by 44position: middledoi
The International Collaboration for Research methods Development in Oncology (CReDO) workshops: shaping the future of global oncology research
The Lancet Oncology 2021cited by 40position: middledoi
Increasing frequency of gene copy number aberrations is associated with immunosuppression and predicts poor prognosis in gastric adenocarcinoma
British journal of surgery 2021cited by 8position: middledoi
Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial
Annals of Oncology 2020cited by 5position: middledoi
Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial
Annals of Oncology 2019cited by 397position: middledoi
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial
The Lancet 2018cited by 1,251position: middledoi
A seven-Gene Signature assay improves prognostic risk stratification of perioperative chemotherapy treated gastroesophageal cancer patients from the MAGIC trial
Annals of Oncology 2018cited by 39position: middledoi
Mismatch Repair Deficiency, Microsatellite Instability, and Survival
JAMA Oncology 2017cited by 520position: middledoi
Testing many treatments within a single protocol over 10 years at MRC Clinical Trials Unit at UCL: Multi-arm, multi-stage platform, umbrella and basket protocols
Clinical Trials 2017cited by 94position: middledoi
Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial
Journal of Clinical Oncology 2016cited by 305position: middledoi
ecancermedicalscience
ecancermedicalscience 2016cited by 15position: middledoi
Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus
Nature Genetics 2012cited by 170position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Matthew Nankivell · University of Padua6 papers (2016–2023)David Cunningham · Centre de recherche en Epidémiologie et Santé des Populations5 papers (2016–2022)William Allum · Royal Marsden NHS Foundation Trust5 papers (2016–2022)Mahesh Parmar · MRC Clinical Trials Unit at UCL4 papers (2017–2023)Heike I. Grabsch · Maastricht University3 papers (2016–2022)Matteo Fassan · University of Padua3 papers (2016–2018)Elizabeth Smyth · National Health Service3 papers (2016–2018)Nicola Valeri · University of Padua3 papers (2016–2018)Andrew Wotherspoon · Royal Marsden Hospital3 papers (2016–2018)Andrea Lampis · University of Padua2 papers (2016–2018)Jens C. Hahne · University of Padua2 papers (2016–2018)Fay Cafferty · Institute of Cancer Research2 papers (2017–2021)Takaki Yoshikawa · University of Tampa2 papers (2021–2022) · 2 papers (2021–2022) · 2 papers (2021–2022) · 2 papers (2021–2022)Clare Peckitt · Royal Marsden NHS Foundation Trust2 papers (2016–2017)Matthew R. Sydes · MRC Clinical Trials Unit at UCL2 papers (2017–2021) · 2 papers (2021–2022)Alicia Okines · Royal Marsden NHS Foundation Trust2 papers (2016–2017)